Clinical Data Presented at American Diabetes Association 82nd Scientific Sessions Reinforce Significant and Durable Benefits of Nevro’s HFX 10 kHz Therapy

SENZA-PDN Randomized Controlled Trial Results From Original 10 kHz Arm Demonstrate Significant and Sustained Outcomes with 10 kHz Therapy at 24-Months Follow-Up REDWOOD CITY, Calif., June 7, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering...

Click to view original post